Document is current
Any future updates will be listed below
-
Authors
Zhu, Yingqian http://orcid.org/0000-0001-7452-1536
Huang, Ce
Zheng, Liang
Li, Qingqing
Ge, Jianli
Geng, ShaSha
Zhai, Miaomiao
Chen, Xin
Yuan, Huixiao
Li, Yang
Jia, Wenwen
Sun, Keping
Li, Yan
Ye, Tong
Zhao, Zhengmei
Liu, Hailiang
Liu, Zhongmin
Jiang, Hua
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04314011 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study
https://doi.org/10.1186/s13287-024-03707-2
-
Funding
Funding for this research was provided by:
Shanghai Zhangjiang National Innovation Demonstration Zone (No. ZJ2018-ZD-004)
Shanghai Pudong New District Health and Family Planning Commissions (No. PW2022B-13)
Peak Disciplines (Type IV) of Institutions of Higher Learning in Shanghai
National Key Research and Development Program of China (No. 2022YFC3601504)
Shanghai Municipal Health Commission (No.202140248)
- License Information
-
More Information
Article History
Received: 8 January 2024
Accepted: 24 March 2024
First Online: 29 April 2024
Declarations
:
: This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. The clinical study of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study was approved by the Human Cell Clinical Research Ethics Committee of Shanghai East Hospital (EC.D(BG)0.020.02.0-2019-008) on October 8, 2019. All patients have provided written informed consent before the beginning of the study.
: All participants enrolled in this study have provided written informed consent for the publication of their anonymized data and related information.
: The authors declare that there is no competing interest.
